Warm‐reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice

“…6 • The same limitations apply to common laboratory or diagnostic techniques used in the investigation of AIHA. 7 • The impact of AIHA on patient's health-related quality of life (HRQoL) is poorly described.…”

mentioning

confidence: 99%

Developing the evidence base for the management of autoimmune haemolytic anaemia (AIHA): the UK experience

et al. 2020

View full text Add to dashboard Cite

“…Delaney posed the question ‘How can we make the blood provided, the safest for patients with warm autoantibodies?' The feeling was that practice was not standardised, so to define a robust answer, a review of current literature and a survey to understand practice were undertaken (Ziman et al, ).…”

Section: Foundation Lecture—chaired By Jo Martin Rcpath and Professomentioning

confidence: 99%

Advances in Transfusion Medicine RCPath, November 2018

Bullock

Hazell

McCullagh

2019

Transfusion Medicine

View full text Add to dashboard Cite

“…They represent 70% of the AIHA [17]. 73.5% of AIHAC are secondary to other diseases (leukemias, lymphomas, lupus) and 26.5% idiopathic [23][24][25][26][27].…”

Section: Warm Autoimmune Hemolytic Anemiamentioning

confidence: 99%

Blood Transfusion in Patients with Immunohaematological Problem

2018

IJCRT

View full text Add to dashboard Cite

The blood transfusion therapy is an essential in the management of hematologic/ oncologic disorders. Although transfusions are not risk free. In fact, this patient may develop alloimmune or autoimmune process during the transfusion support. Alloimmunization is a significant risk of transfusions and is the second leading cause of transfusionassociated death. In fact, the transfused individuals with hematologic/oncologic disorders may develop red blood cell alloantibodies, which can complicate pretransfusion testing, delay blood product availability, and lead to transfusion reactions. The autoimmune haemolytic anaemia may be produced by cold and warm autoantibodies and may mediate intravascular or extravascular autoimmune haemolysis in haematology/oncology patients. Many immunohematology tests performed by blood banks, including antibody screening, direct antiglobulin tests, eluates, and minor antigen phenotyping, are used in the assessment of haematology/oncology patients who require transfusion care, or in whom an alloimmune or autoimmune process is suspected. The tests that form the basis for transfusion compatibility and antibody identification are not always well understood, nor are their interpretations always straightforward. A better understanding of testing realized in the immunohematology laboratory will allow haematology/oncology providers to make informed decisions on the risk/benefit ratio of transfusion for their individual patients. Further, this understanding will allow improved communication between haematology/oncology providers and the transfusion Service in instances of transfusion histories, new antibody formation, and unexpected adverse transfusion sequelae.

show abstract

Warm‐reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice

Abstract: There is wide variability in immunohematology testing and RBC selection practices for patients who have WAAs (with or without AIHA). Future studies are needed to evaluate and compare the effectiveness of different testing algorithms and transfusion strategies.

Cited by 30 publications

References 88 publications

Developing the evidence base for the management of autoimmune haemolytic anaemia (AIHA): the UK experience

Developing the evidence base for the management of autoimmune haemolytic anaemia (AIHA): the UK experience

Advances in Transfusion Medicine RCPath, November 2018

Blood Transfusion in Patients with Immunohaematological Problem

Contact Info

Product

Resources

About